Home › Research › Prevention and risk
Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline
Stuenkel CA, Davis SR, Gompel A, Lumsden MA, Murad MH, Pinkerton JV, Santen RJ.. The Journal of clinical endocrinology and metabolism, 2015-10-07
Topic: Risk, prevention and care in population studies
Plain-language summary
Objective The objective of this document is to generate a practice guideline for the management and treatment of symptoms of the menopause. Participants The Treatment of Symptoms of the Menopause Task Force included six experts, a methodologist, and a medical writer, all appointed by The Endocrine Society. Evidence The Task Force developed this evidenced-based guideline using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe the strength of recommendations and the quality of evidence. The Task Force commissioned three systematic reviews of published data and considered several other existing meta-analyses and trials. Consensus process Multiple e-mail communications, conference calls, and one face-to-face meeting determined consensus. Committees of The Endocrine Society, representatives from endorsing societies, and members of The Endocrine Society reviewed and commented on the drafts of the guidelines. The Australasian Menopause Society, the British Menopause Society, European Menopause and Andropause Society, the European Society of Endocrinology, and the International Menopause Society (co-sponsors of the guideline) reviewed and commented on the draft. Conclusions Menopausal hormone therapy (MHT) is the most effective treatment for vasomotor symptoms and other symptoms of the climacteric. Benefits may exceed risks for the majority of symptomatic postmenopausal women who are under age 60 or under 10 years since the onset of menopause. Health care professionals should individualize therapy based on clinical factors and patient preference. They should screen women before initiating MHT for cardiovascular and breast cancer risk and recommend the most appropriate therapy depending on risk/benefit considerations. Current evidence does not justify the use of MHT to prevent coronary heart disease, breast cancer, or dementia. Other options are available for those with vasomotor symptoms who prefer not to use MHT or who have contraindications because these patients should not use MHT. Low-dose vaginal estrogen and ospemifene provide effective therapy for the genitourinary syndrome of menopause, and vaginal moisturizers and lubricants are available for those not choosing hormonal therapy. All postmenopausal women should embrace appropriate lifestyle measures.
What this study adds
Evidence grade: High
This is a pooled review. This clinical practice guideline states that current evidence does not justify the use of menopausal hormone therapy to prevent dementia. It reports no treatment or cure for Alzheimer's disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Stuenkel, C. A., Davis, SR., Gompel, A., Lumsden, M. A., Murad, M. H., Pinkerton, J. V., et al. (2015). Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. The Journal of clinical endocrinology and metabolism. https://doi.org/10.1210/jc.2015-2236
Vancouver
Stuenkel CA, Davis SR, Gompel A, Lumsden MA, Murad MH, Pinkerton JV, et al. Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. The Journal of clinical endocrinology and metabolism. 2015. doi:10.1210/jc.2015-2236. PMID: 26444994.
BibTeX
@article{stuenkel2015-26444994,
author = {Stuenkel, C. A. and Davis, SR. and Gompel, A. and Lumsden, M. A. and Murad, M. H. and Pinkerton, J. V. and Santen, R. J.},
title = {{Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline}},
journal = {The Journal of clinical endocrinology and metabolism},
year = {2015},
doi = {10.1210/jc.2015-2236},
pmid = {26444994},
url = {https://doi.org/10.1210/jc.2015-2236}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- They should screen women before initiating MHT for cardiovascular and breast cancer risk and recommend the most appropriate therapy depending on risk/benefit considerations.
- Current evidence does not justify the use of MHT to prevent coronary heart disease, breast cancer, or dementia.
- Other options are available for those with vasomotor symptoms who prefer not to use MHT or who have contraindications because these patients should not use MHT.
- Low-dose vaginal estrogen and ospemifene provide effective therapy for the genitourinary syndrome of menopause, and vaginal moisturizers and lubricants are available for those not choosing hormonal therapy.
- All postmenopausal women should embrace appropriate lifestyle measures.
Why it matters
This clinical practice guideline states that current evidence does not justify the use of menopausal hormone therapy to prevent dementia. It reports no treatment or cure for Alzheimer's disease.
New to this subject? Start with our plain-English guide: Prevention →
Study details
- Study designmeta-analysis
- Evidence strengthHigh
How this study scored 69/100
Published in a peer-reviewed journal, and it is a meta-analysis pooling many studies. Scored zero for sample size, effect reported and studied in people because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (The Journal of clinical endocrinology and metabolism) |
| Journal's citation record | 3 / 4 | The Journal of Clinical Endocrinology & Metabolism: journal h-index 490 (OpenAlex, 2026-10-29) |
| Study design | 12 / 12 | A meta-analysis pooling many studies |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2015 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | A review of other studies — randomization is not credited here |
| Times cited | 6 / 7 | Cited 881 times (OpenAlex, 2026-10-10) |
| Citations per year | 5 / 5 | 67.8 citations a year over 13 year(s) since 2015 |
| Impact for its field and year | 6 / 6 | Cited 46.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 2 other studies in this library |
| Still being cited | 4 / 4 | Cited 236 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Richard J. Santen: h-index 90 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of California San Diego: institution h-index 1,852 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 7 institution(s) in 4 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 26444994) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 69 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
2 studies in the alzhub library list this one in their references.
Related studies in Prevention and risk from nearby years
Also in Prevention and risk
269 studies in the library are filed under Prevention and risk with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Prevention and risk hub.